肺癌创新Quickfire挑战
$750,000 (¥4.7M) in Grants + Residency + Mentoring
Awardees
DNX生物制药
DNX Biois a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.
Hawkeye Bio
Hawkeye Bio启动于2018年在加州commercializ吗e novel, clinically validated breath analytics for the detection of lung cancer. Lung cancer is the leading cause of cancer deaths among both men and women[1]. Lung cancer often has no symptoms until it has metastasized, because there are few specialized nerves (pain receptors) in the lungs. Lung cancer is diagnosed late 84% of the time, when treatment options are more limited. Despite progress in biomarker discovery and targeted therapy, lung cancer mortality remains unacceptably high worldwide. Hawkeye’s mission is lung cancer interception to bring about a solution to this problem.
NE Scientific
NE Scientific是一家位于波士顿的初创公司，开发了一种外科指导软件，用于在肝脏和肺部肿瘤经皮消融过程中支持医生靶向组织。Accublate（TM）指导软件在消融过程中实时模拟物理学，并以特定于患者的方式确定消融体积。该信息是在术中生成的，并覆盖为患者的CT图像，帮助医生完成所有恶性组织的完整治疗。
[1]HawkeyeBio.com, 2019
The Challenge
一般人吸气432 liters of oxygen every single day, a vital component in sustaining the trillions of cells in the body. Humans can survive just a few minutes without oxygen. To that end, it is essential that we protect our lungs.
在暴露于致癌物之后，有没有办法清洁肺部，就像牙刷在进食后清洁嘴吗？是否有一种方法可以像防晒霜那样将肺部免受致癌物的影响，使我们免受损坏的紫外线暴露？这些是约翰逊和约翰逊创新希望通过肺癌创新Quickfire挑战引发的一些挑衅性思想。
Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year. Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defenses and result in inflammation, genomic changes and ultimately tumor growth. Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.
Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritizing lung health. How do we leverage the totality of science and technology to achieve comprehensive lung health - to ultimately prevent, intercept and cure lung cancer?
多达三个具有最佳想法，技术或解决方案的创新者，可以改善与预防，拦截或治愈肺癌相关的人类医疗保健a total of $750,000 in grants, a在JLABS @ Shanghai（可选）居住一年的代金券，包括实验室长凳，工作站和进入JLABS社区的访问以及Johnson＆Johnson Innovation和/或其分支机构的指导。
Reward
- JLABS @上海的1年居留权（可选）
- Johnson＆Johnson Innovation和/或其分支机构的专家的指导和指导
Areas of Interest
We encourage applications from innovators working on all aspects of lung health, including solutions focused on Lung Cancer:
- Prevention: Approaches to identify risks and for warding off onset of lung cancer
- Interception: Arrest lung cancer as it develops, prior to clinical onset
- Cures: Completely eliminate presence of lung cancer and reverse damage to restore full health
请记住，不要太大或太早以供考虑。在评估期间，还将考虑清楚地描述实现这些目标的概念或前进的概念或途径的应用。
We are interested in applications addressing the full spectrum of lung health. Specific areas of interest include, but are not limited to:
- To develop approaches to reduce, prevent, or protect from exposure to respiratory carcinogen, including novel approaches to smoking cessation
- 开发方法来测量呼吸致癌物的暴露和生物学作用
- To develop diagnostics/biomarkers to detect pre-cancers or early-stage malignant lesions
- To develop approaches, including surgical, medical, behavioral, digital or others, to prevent or intercept lung carcinogenesis
- To discover new tools for diagnosis and extirpation of curable lung cancers
- To develop new treatments or treatment modalities for the cure of lung cancer
Approaches should include the following areas:
- 药品
- 消费产品
- Medical devices
- Global public health
- Health technologies
- Cross-sector initiatives – an integration of one or more the aforementioned areas of focus
Application Process
Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential impact
- Uniqueness of solution & level of competition in current market
- 技术的质量和可行性
- Team credibility & capabilities
- Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)
Timeline
为什么这个挑战对我们很重要
We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.
FAQs
Q: What if I’m having trouble accessing the portal/website?
A: Make sure your browser is up to date and accepting cookies. You can contact customer service at[email protected]if you are having technical difficulties as well.
Q: Is residency at JLABS @ Shanghai required?
A: No. Residency is encouraged but optional.
Q: Do I need to reside in Shanghai or a Chinese entity in order to apply?
A: No. We are seeking innovations globally.
Q: For prizes involving residency at JLABS, what does that entail and for how many people?
A: For challenges involving residency at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees, additional footprint can be rented.
Q: For prizes involving residency at JLABS, are there any expenses not covered by JLABS?
A: Each applicant will be required to submit to a background check, which is subject to a minimal fee. We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS. There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.
Q: Will JLABS pay for my living costs, relocation or visas?
A: No, any additional fees and paperwork are up to the winner.
问：我可以作为我的应用程序的一部分提交支持文档（例如视频）吗？
A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.
Q: Is it ok if some of the information I submit is confidential?
答：不要提交机密信息。仅应提交非固定信息，并且您提交的任何内容都将被视为非机密。
Q: What happens with IP (Intellectual Property)?
答：由于这是一个没有字符串的安排，因此JLABS不会获得任何IP。任何IP创建和/或保护仍然是发明者的唯一责任。
Q: Is a patent required to apply?
A: No, a patent is not required to apply. However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.
Q: What kind of science / technology is appropriate for the Challenges?
A: We encourage all to apply. Find out more about what areas we desire to explore here:https://www.jnjinnovation.com/partnering
问：谁有资格申请？
A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.
问：应用的具体标准是什么？
A: Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:
- Potential impact
- Uniqueness of solution & level of competition in current market
- 技术的质量和可行性
- Team credibility & capabilities
- Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)
Q: Who can I contact if I have questions about the Challenges or the application process?
A: Please contact[email protected]with any questions.
问：我在哪里申请？我必须一次坐下来完成申请吗？
答：申请https：//www.2574design.com/form/lung-qfc-apply。您可以保存工作并登录，以便在需要时在以后的时间完成。
关于约翰逊和约翰逊创新，jlabs
Johnson＆Johnson Innovation，JLABS（JLABS）是一个全球开放创新生态系统的网络，使和授权创新者能够为世界各地的患者创造和加速挽救生命，增强生命的健康和健康解决方案。JLABS通过为新兴公司提供最佳环境来实现这一点明天的突破性医疗解决方案。在JLABS，我们珍视伟大的想法，并热衷于消除成功的障碍，以帮助创新者释放其早期科学发现的潜力。JLABS是一个无弦的模型，这意味着企业家可以在坚持其知识产权的同时自由发展科学。JLABS向包括药品，医疗设备，消费者和数字健康部门在内的广泛医疗保健领域开放企业家。
jlabscurrently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco. JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe. For more information about JLABS, please visitwww.2574design.com.
About Johnson & Johnson (China)投资有限公司
强生公司
强生是全球业务分布广泛、综合性的跨国医疗保健企业，业务涉及消费品、制药、医疗器材三大领域，1985年在华创立了第一家合资企业。强生遵循企业信条的价值观，致力于践行“关爱全世界,关注每个人”的健康愿景，以领先的科技研发创造创新的理念、产品和服务，为改善人类健康和福祉而不懈努力。每天，强生遍布世界各地的员工，与他们的合作方一起，为全球消费者和病患带来更健康、更快乐、更长寿的生活。